Tsuda and colleagues reported that gene fusions involving TFE3 can activate MET signaling; hence, they proposed that MET inhibitors may be potential candidates for managing alveolar soft part sarcoma [47]. The gene discussed is MET; the disease is alveolar soft part sarcoma.